{"pub_date": "2016-05-17T00:00:00Z", "subsection_name": "DealBook", "lead_paragraph": "The more important question for shareholders, though, is whether Pfizer\u2019s chief executive, Ian C. Read, will break up Pfizer.", "print_page": null, "document_type": "article", "byline": {"person": [{"rank": 1, "organization": "", "lastname": "CURRIE", "firstname": "Antony", "role": "reported"}], "original": "By ANTONY CURRIE"}, "multimedia": [], "section_name": "Business Day", "headline": {"content_kicker": "Breakingviews", "main": "Pfizer Could Get Its Money\u2019s Worth Out of Anacor Deal", "kicker": "Breakingviews"}, "source": "The New York Times", "blog": [], "word_count": "363", "web_url": "http://www.nytimes.com/2016/05/17/business/dealbook/pfizer-could-get-its-moneys-worth-out-of-anacor-deal.html", "slideshow_credits": null, "news_desk": "Business", "type_of_material": "News", "snippet": "The more important question for shareholders, though, is whether Pfizer\u2019s chief executive, Ian C. Read, will break up Pfizer.", "_id": "573a121438f0d84a2689a66a", "abstract": null, "keywords": [{"rank": "1", "name": "subject", "value": "Mergers, Acquisitions and Divestitures", "is_major": "N"}, {"rank": "2", "name": "organizations", "value": "Pfizer Inc", "is_major": "N"}, {"rank": "3", "name": "persons", "value": "Read, Ian C", "is_major": "N"}, {"rank": "4", "name": "organizations", "value": "Anacor Pharmaceuticals Inc", "is_major": "N"}]}